Hunter Immunology Limited

The University of Newcastle Research Associates Limited

Auspharm International Limited

Provalis UK Limited

Hunter Technology Limited

Flustat Pty. Ltd.

Broncostat Pty. Limited

Pneumobiotics Pty. Ltd.

Robert Llewellyn Clancy

Gerald Toh Pang

Allan William Cripps

Margaret Lorraine Dunkley

Campbell Witt

Daniel Stiel

Jennelle Kyd

Phillip Comans

Maree Gleeson

Elahi Shokrollah

Diana Christine Otczyk

Robert Batey

Gerald Pang

Provided are non-typeablevaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a monobacterial vaccine. Bacterial strains for use in the vaccines of the present application are also provided.

[object Object]

There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable(NTHi) vaccine. The vaccine is typically an oral whole killed NTHi vaccine.

Treatment or prophylaxis of asthma

The present invention is concerned with novel compositions and vaccines useful for prophylactic an/or therapeutic treatment of mucosal infections, and in particular it is concerned with oral vaccines and with methods of enhancing mucosal resistance to infection or for treating established infections, of the respiratory tract.

Compositions and methods for treatment of mucosal infections

There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonization of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each microbial isolate, and the effectiveness of the isolates in reducing infection of a mucosal surface by the microbe to provide clearance data for each microbial isolate. An isolate, the activation data and clearance data for which correlate and is optimal for generating mucosal immunity against the microbe compared to the, or each, other of the isolates, or an isolate the activation data for which is optimal and a further isolate the clearance data for which is optimal, compared to the, or each, other of the isolates, respectively, is then selected for use in the vaccine. There is also described a method for providing an oral killed vaccine against abnormal microbial colonization of a mucosal surface, comprising evaluating the capacity of a plurality of different isolates of a microbe to induce expression of IL-10 and IL-12 in antigen responsive cells. At least one isolate is selected that induces optimal expression of IL-12 relative to IL-10 compared to the, or each, other of the isolates, respectively, for use in the vaccine.

Oral killed vaccines and method for providing same

The present invention relates to novel oral compositions and vaccines, and in particular to oral vaccines for the prevention or therapy of candidiasis.

Compositions and methods for treatment of candidiasis

A novel antigen fromis provided. The use of the antigen in detecting/diagnosingas well as its use in eliciting an immune response are also provided.

The present invention relates to methods of identifying potentially therapeutic compounds for the treatment of hepatic disorders, preferably alcohol-induced hepatitis. Further, use of mammals in such methods, therapeutic compounds identified using said methods and the use of a Chinese Herb, CH-100, in the treatment of hepatic disorders, particularly alcohol-induced hepatic disorders, are described.

Method of identifying therapeutic compounds for a treatment of hepatic disorders

The present invention is concerned with methods for determining predisposition to infection in a subject exposed to stressors. In particular the present invention is concerned with methods of assessing the risk of susceptibility to infection in a subject by monitoring the levels of IgA and IgA1.

Predisposition to infection associated with intense exercise or other stress

In vitro test for Helicobacter pylori

Red blood cells or derivatives thereof such as ghost preparations, whole cell membrane preparations or fragments thereof, can act as a potent carrier for orally administered antigens. Mucosal immunity in particular can be effectively induced against such viruses as influenza when adsorbed to chicken red blood cells and orally administered.

Oral vaccine comprising antigen surface-associated with red blood cells

The present invention contemplates a method for detecting contempory infection by H. pylori in a mammal comprising contacting a mucous secretion from said mammal with an antigen component from H. pylori for a time and under conditions sufficient for an IgG antibody in said mucous secretion specific to said antigen component to form a complex therewith and then subjecting said complex to a detecting means. Preferably, the antigen component is immobilized onto a solid support.

Growing community of inventors

Newcastle, Australia

Robert Llewellyn Clancy